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Available online 14 March 2017Background: Lifelong antiretroviral therapy (ART) (Option B+) is recommended for all HIV-infected pregnant/
postpartumwomen, but high adherence is required to maximize HIV prevention potential and maintain mater-
nal health. Mobile health (mHealth) interventionsmay provide treatment adherence support for women during,
and beyond, the pregnancy and postpartum periods.
Methods and design: We are conducting an unblinded, triple-arm randomized clinical trial (Mobile WACh X) of
one-way short message service (SMS) vs. two-way SMS vs. control (no SMS) to improvematernal ART adherence
and retention in care by 2 years postpartum.Wewill enroll 825women fromNairobi andWestern Kenya.Women
in the intervention arms receive weekly, semi-automated motivational and educational SMS and visit reminders
via an interactive, human-computer hybrid communication system. Participants in the two-way SMS arm are
also asked to respond to a question related to themessage. SMS are based in behavioral theory, are tailored to par-
ticipant characteristics through SMS tracks, and are timed along the pregnancy/postpartum continuum. After en-
rollment, follow-up visits are scheduled at 6 weeks; 6, 12, 18, and 24 months postpartum. The primary outcomes,
virological failure (HIV viral load ≥1000 copies/mL), maternal retention in care, and infant HIV infection or death,
will be compared in an intent to treat analysis. We will also measure ART adherence and drug resistance.
Discussion: Personalized and tailored SMS to support HIV-infected women during and after pregnancy may be an
effective strategy to motivate women to adhere to ART and remain in care and improve maternal and infant
outcomes.
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In 2015, 110,000 children became infected with HIV in 21 of the
highest burden countries in sub-Saharan Africa, primarily through
mother-to-child HIV transmission (MTCT) [1]. This estimate represents
a 60% reduction in MTCT over a six-year period, due to provision of an-
tiretroviral regimens to women and infants in prevention of mother-to-
child HIV transmission (PMTCT) programs [2].
Lifelong antiretorviral therapy (ART) for all HIV-infected pregnant
women, known as PMTCT Option B+, was recommended in 2013.
This efﬁcacious PMTCT regimen requires consistent retention and ma-
ternal adherence to treatment. However, retention in adult ART pro-
grams wanes over time, with an estimated 30% of patients being lost
Fig. 1. Formative research for SMS adaptation and reﬁnement.
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loss to follow-up varies, ranging from 19 to 85% [4,5]. Implementation
of Option B+ in PMTCT programs has resulted in higher ART coverage
and lower MTCT rates, but barriers to retention and adherence persist
[6–9]. ART adherence may decline following delivery and throughout
the ﬁrst year postpartum [8]. Mothers may lose motivation to continue
ART for their own health after they stop breastfeeding [10,11]. Poor ART
adherence leads to virologic failure and potential development of ART
resistance, limiting effectiveness of ART regimens.
In general, adherence to ART and retention in care are affected by
sociobehavioral, clinical, and health systems factors, including self-efﬁ-
cacy, stigma, partner and family support, side effects, and patient-pro-
vider interactions [11–14]. Treatment support to encourage adherence
and retention is offered at clinic visits; however, clients may face chal-
lenges at home and barriers to clinic attendance that could be addressed
by tailored treatment support via phone messaging services.
Mobile health (mHealth) interventions provide an attractive ap-
proach to enhance HIV treatment support for Option B+ PMTCT. In a
meta-analysis of 16 randomized clinical trials (RCTs) of short message
service (SMS) interventions, including several studies on HIV in sub-
Saharan Africa, SMS interventions improved medication adherence for
chronic conditions N 2-fold [15]. SMS was found to be effective for in-
creasing antenatal and postnatal attendance among HIV-infected
women and improving early initiation and exclusive breastfeeding
[16]. However, the effect of SMS onmaternal or infant outcomes, includ-
ing maternal ART adherence to Option B+ has not been assessed in
RCTs. In addition, few mHealth interventions in resource-limited set-
tings target or tailor SMS content, which may limit their potential [17].
We adapted an interactive mHealth human-computer hybrid com-
munication system initially designed for maternal child health (Mobile
Solutions forWomen's and Children's Health,MobileWaCh) [18], to ad-
dress PMTCT-ART related outcomes in Mobile WACh X. We designed a
3-armed RCT to determine the impact of one-way SMS vs. two-way
SMS vs. control (no SMS) on maternal ART adherence, retention in
care, and infant HIV infection or death during 2-year postpartum fol-
low-up.
2. Material and methods
2.1. Study design and population
The RCT is conducted in 3 sites in Kenya, 2 rural sites in the Nyanza
region (Ahero County Hospital and Bondo sub-County Hospital), and 1
urban site in Nairobi (Mathare North Health Center). Women are eligi-
ble to participate if they are ≥14 years old, attending antenatal care
(ANC), HIV-infected, ≤36weeks gestation, have daily access to amobile
phone (own or shared)with a Safaricom SIM card, are willing to receive
SMS, plan to reside in the area for two years postpartum, plan to receive
bothmaternal child health (MCH) and HIV care at the facility they were
recruited from, and are not enrolled in any other studies. Women who
are illiterate but are comfortable with another person reading them
the SMS are eligible for the study. In April 2016, eligibility criteria
were expanded to include women N36 weeks gestation.
Study procedures and data collection instrumentswere approved by
ethical review committees at the Kenyatta National Hospital/University
of Nairobi and the University of Washington. Participants provide writ-
ten informed consent prior to enrollment in the study.
2.2. Randomization
The RCT involves 825 participants randomized to one-way SMS,
two-way SMS, or control (no SMS) using 1:1:1 allocation. Randomiza-
tion is stratiﬁed by site (no more than 399 women will be randomized
from any site). A randomization list was generated using variable
block sizes in Stata 12.1 ralloc.ado v.3.5.2. Allocation codes were placed
in sequentially numbered sealed, opaque envelopes by site which aresequentially distributed to and opened by participants. Study investiga-
tors are blinded to block number, size, and sequence.
2.3. Intervention
Women randomized to one-way SMS or two-way SMS receive
weekly, automated motivational and educational messaging as well as
clinic visit reminders. SMS for participants in the two-way SMS arm
also include a question related to the message topic that solicits, but
does not require, a response. In addition, women in the two-way arm
can communicate with the study nurse via SMS at any time.
Formative research was conducted to develop SMSmessages for the
Mobile WACh X RCT. MCH-related SMS were adapted from a prior trial
(Mobile WACh) which evaluated one-way SMS vs. two-way SMS vs.
control as a strategy to improveMCHoutcomes in Kenya, andHIV-relat-
ed SMS were newly developed and tested [18]. SMS message content
was adapted through a series of focus group discussions (FGDs) with
HIV-infected pregnant and postpartum women, key informant in-
depth interviews (IDIs) with health providers, and IDIs with male part-
ners of HIV-infectedwomen. (Fig. 1) FGDswere conducted until satura-
tion was achieved by site (urban and rural). Results from these studies
were used to determine acceptability and comprehension of pre-devel-
oped SMS themes and content, elicit suggestions for additional message
themes and/or phrasing, understand and address concerns about SMS,
and reﬁne SMS. Results from qualitative studies are summarized else-
where (manuscript under review).
SMS are managed through a semi-automated, open source human-
computer hybrid communication SMS system developed by investiga-
tors at the University of Washington (Fig. 2). The platform incorporates
Reinforcement Theory [19], in this case positive reinforcement theory,
to motivate completion of tasks by study staff, such as message re-
sponses, patient tracking updates, and coding of SMS for streamlined
monitoring and evaluation. The system is a custom web application
hosted on a password protected virtual private server written using
the Django web-framework and Anguler.js. SMS are sent to, and re-
ceived by, participants free of charge on a short code through a Hyper-
text Transfer Protocol (HTTP) to SMS gateway maintained by a
Kenyan premium rate service provider (Fig. 3). Study staff access the
system through a desktop web browser and are able to respond to in-
coming SMS messages, monitor upcoming and missed visits, document
phone calls and translate messages for uniformity in understanding
message content. The system also includes an interface that provides a
summary of participant details (maternal age, expected or actual deliv-
ery date, pregnancy or postpartum status, ART status, family planning
method, and randomization arm) for study staff to have essential infor-
mation about women when they are using the system. Pre-pro-
grammed SMS are automatically sent to women randomized to one-
way and two-way arms weekly at the participant's preferred time of
day, day of week, and language (English, Kiswahili, or Dholuo).
Fig. 2. SMS message themes and tracks.
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pregnancy support and education, birth preparedness and delivery, in-
fant feeding, infant health, family planning, and appointment reminders
(Fig. 4). SMS are based on the Health Belief Model and Social Cognitive
Theory [20,21], in order to provide tailored and actionable education,
support, counseling, and reminder messages designed to reinforce
health behaviors such as clinic attendance and ART adherence. SMS
topics are scheduled according to antenatal/postnatal timing and ART
experience. Visit reminder SMS are sent 3 days before the scheduled
appointment date and congratulatory SMS are sent when visits
are attended. Additional reminders are sent 3 and 6 days after a missed
visit.
RCT participants are asked at the time of consent whether they
would like to receive SMS that contain HIV-related terms (such as ‘med-
ications’, ‘infection’) and topics (side-effects, PMTCT, infant prophylaxis,
infant testing). In order to protect patient conﬁdentiality and prevent
involuntary disclosure, women are only eligible to receive HIV-related
content if they have disclosed their status to anyone who has access to
their phone or if no one has access to their phone. Women can elect
one of the following options: 1) not receive any overt HIV-related con-
tent, 2) receive overt HIV-related SMS only in response to a question
asked by the participant to the study nurse, or 3) receive overt HIV-
related SMS as part of regular weekly SMS sent to participants and in
response to a question asked by the participant to the study nurse.
Preferences on HIV-related content are asked of all women prior to
randomization.Fig. 3. SMS system architecture.Women (1) receive SMSmessages on Safaricom using the stand
over SS7 from Safaricom (2) and forwards them to the SMSmanagement system on a virtual p
women via a laptop and mobile data (5).Examples of SMS developed though iterative formative research are
shown in Table 1. For each SMS, we developed up to 16 versions, cus-
tomized based on the intervention arm (one-way or two-way), prefer-
ence for HIV-related messaging (overt or covert), and participant
“track” based on participant characteristics (previously on ART, newly
initiating ART, or adolescent track). Fig. 4 summarizes themessage con-
tent and tracks. One-way and two-way SMS are the same with the ex-
ception of the addition of a question that prompts women to reply in
the two-way SMS arm. Participants are entered into one of themessag-
ing tracks at enrollment. Additionally, a separate track was developed
for participants who experience a fetal or infant loss after enrollment
and provides women with similar SMS that do not mention the baby.
If study staff are informed of the loss, they call the participant to offer
condolences and ask if she wants to continue in the study. Women
who opt to continue study participation in the intervention arms are
also asked if theywant to continue receiving SMS, and if so, are switched
to the fetal/infant loss track. While the SMS database continues to ex-
pand as the study progresses, to date, we have 676 unique English ver-
sions of SMS that are sent to women between 16 weeks gestation and
45 weeks postpartum: 236 antenatal SMS; 400 postpartum SMS; and
40 visit reminder, condolence, and system administrative SMS. The
full message database is available on request from the authors and
will be made publicly available by the completion of the study.
Women can stop receiving SMS at any time by sending the message
“STOP” to the study short code; they can elect to either stop all SMS or
stop education and counseling SMS but continue with visit reminders.ard GSM/SMS protocol. The Kenyan premium service provider (3) receives SMSmessages
rivate server (4). Study staff can access the SMSmanagement system to reply to SMS from
Fig. 4. SMS system screenshot.
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Women are enrolled during pregnancy and have follow-up visits
scheduled at 6 weeks; 6, 12, 18, and 24 months postpartum. At each
study visit, women are administered a standardized survey on a tablet
using Open Data Kit (ODK). A summary of survey data at each visit,
and instruments used for collection are described in Table 2. All clinical
procedures, including MCH and HIV related care, are provided by clinic
staff; no clinical care is provided by the study. Between study visits,
study staff abstract patient records to inform personalized, dynamic
messaging. Study staff record appointments, deliveries, clinic visits,
medication reﬁlls, infant immunizations, or any clinic contact with
study participants.
Maternal blood samples are collected at enrollment for HIV viral
load, and for CD4 count at enrollment, 12 and 24 months postpartum.
HIV viral load at enrollment is conducted by the study; follow-up assays
are performed as part of the standard of care every 6months and results
are abstracted from maternal records. All maternal HIV viral loads
conducted by the study and the program are performed at the
Kenya Medical Research Institute (KEMRI)/Centers for Disease
Control and Prevention (CDC) in Kisumu or Nairobi, Kenya using the
Roche COBAS® TaqMan® Analyer or COBAS® TaqMan® Version 2.0
(CAP/CTMv2.0) platform. In the event that HIV viral load cannot be per-
formed for any reason as part of the standard of care, viral loads are per-
formed by the study. Infant dried blood spots are collected at each
postpartum study visit. Infant HIV DNA polymerase chain reaction
[PCR] testing is conducted as part of PMTCT programs at 6 weeks,
6 months, and 12 months. Programmatic infant HIV test results are ab-
stracted fromclinic records. The studywill also test infants at 24months
using 4th generation HIV tests.
Since retention in care is a primary trial outcome, retention efforts
and contact with study participants are minimized in order to avoid
contamination of the intervention. Phone numbers of participant con-
tacts and locator information following a home visit are collected at
enrollment, to re-establish contact at 24 months postpartum for partic-
ipants who are lost to follow-up. In addition, phone calls are made to all
participants at 1 month following their expected delivery date to deter-
mine delivery date and align postpartummessages. Phone calls are alsomade at 12 months to all women, and at 24 months if women miss the
exit study visit. In addition, for severe adverse events the study team
calls participants to learn more about the events and evaluate interven-
tion relatedness.
3. Outcomes and statistical analyses
The primary study outcomes arematernal virologic failure, maternal
retention in care, and infant HIV infection or death; secondary outcomes
includematernal ART adherence and drug resistance (Table 3). Clinical,
laboratory, and behavioral outcomes are captured via participant
surveys and data abstracted from MCH booklets, HIV clinic records
and registers for PMTCT, labor and delivery, pharmacy, and peer
counseling (Mothers2Mothers). Women initiating ART who have
≥1000 copies/mL 6 months after ART initiation will be classiﬁed as hav-
ing virologic failure. Retention in care will be evaluated at 12 and
24 months postpartum and deﬁned as the proportion of clinic visits
attended within 2 weeks of the scheduled date. ART adherence will be
calculated based on data abstracted frompharmacy records (proportion
of days covered for each reﬁll interval) and self-reported surveys (pro-
portion of doses missed in the last 30 days at each study visit).
Women are classiﬁed as having antiretroviral drug resistance if resis-
tancemutations are detected fromwomenwith HIV RNA levels exceed-
ing 200 copies/mL using an oligonucleotide ligation assay (OLA) capable
of detecting codon mutations conferring resistance to non-nucleoside
reverse transcriptase inhibitors (NNRTI) (K103N, Y181C, and G190A)
or nucleoside/tide reverse transcriptase inhibitors (NRTI) tenofovir
(K65R) lamivudine/emtricitabine (M184V). These OLA probes are opti-
mized for HIV subtypes A, D, and C common in Kenya [22].
Intention-to-treat analyses will be used to conduct the primary sta-
tistical analyses; we will compare each intervention arm (one-way and
two-way SMS) individually to the control arm. In addition, per-protocol
analyses will be conducted which exclude women who request to stop
receiving SMS and those who require additional retention efforts
(phone call or home tracing) at 24 months postpartum and to
compare a composite intervention group (one- or two-way SMS vs. con-
trol). Chi-square and Kruskal-Wallis tests will be used to compare base-
line characteristics in each arm and determine whether randomization
Table 1
SMS topics and examples included in Mobile WACh X.
Topic Example SMS
Message preamblea bNameN, it is bnurseN from bxN clinic
Medication adherence Your health is very important. Take time each
day for your health. If you are having challenges,
let us know. Are you having any challenges this
week?
HIV medication (overt)b Your health is very important. Make sure to take
your medication every day and come in for
more when you need them. If you are having
challenges let us know. Are you having any
challenges with your medications? When are you
due to come in for more?
General encouragementc If you are having any health concerns we are
available to help
Visit reminder It's time for your clinic visit in bdaysN days on
bdateN. If you have any questions, ask the nurse.
Are you planning to come in to clinic on this date?
Missed visit We missed you in clinic today. You are due for
your visit. Please come in. Are you having trouble
getting to clinic? When will you come in?
Attended visit Great job coming in for clinic. You are taking
good care of both you and your growing baby.
Are you feeling well? Do you have any concerns?
Infant feeding Breastfeeding a baby right after birth helps the
milk come. The ﬁrst yellow sticky milk has
many vitamins & cleans out the stomach. Milk
has all the water the baby needs, avoid other
liquids. Are you planning to breastfeed?
Infant immunization reminder Your baby will receive important vaccines at the
next visit. Please bring your book and ask your
nurse to check you receive everything. Do you
have any questions?
Family planning The IUCD or coil is a small device for family
planning. Easy to put in, safe and very effective
for years but can be removed at any time! Ask
about the coil at your family planning visit. Do
you know anyone who has the coil?
Birth preparedness counseling Regular, strong contractions are a sign of labour.
If you feel strong tightening of your belly,
leaking of ﬂuid or any bleeding go to the clinic.
Don't wait. Do you feel any contractions?
Italics indicate additional SMS content included in messages sent to women in the two-
way arm.
a All SMS initiated by the Mobile WACh X system start with this introduction, followed
by the topic speciﬁc message.
b SMS content included with other messages, but not sent on its own.
c HIV-related SMS are only sent to women who elect and provide speciﬁc consent to
receive these types of messages.
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pare virologic failure 6months after enrollment (time starting 6months
post-enrollment), infant HIV infection or death, and incidence of drug
resistance. Chi-square tests will also be used to compare proportions
of women in each arm who develop resistance by 24 months postpar-
tum. Logistic regression will be used to compare differences in theTable 2
Survey topics, timing of administration, and instruments used.
Survey topic Timing
Demographics Enrollment
Antiretroviral therapy use, adherence, and knowledge All study visits
Disclosure All study visits
Social support All study visits
Stigma All study visits
Maternal depression All study visits
Intimate partner violence All study visits
Maternal health All study visits
Family planning All study visits
Food security All study visits
Use of technology Enrollment and 24 months po
Infant feeding practices Enrollment and 24 months poproportion of women lost to follow-up in each arm and ANOVA will
be used to compare completeness of visit attendance at 12 and
24months postpartum. ANOVAwill also beused to compare ART adher-
ence at 6, 12, and 24 months postpartum.
Wewill conduct activity-based costing to assess direct medical costs
associated with the intervention using World Health Organization
(WHO) guidelines, including personnel, supplies, services, space, and
community awareness and mobilization. Treatment costs incurred due
to treatment failure and drug resistance, and time for study staff to
reply to one-way and two-way SMS will also be measured. Direct
non-medical costs (transportation costs, user fees) and indirect costs
quantifying the time loss and lost wages for patients to seek care will
be assessed in surveys. Costs will be incorporated into a cost-effective-
ness model that will measure incremental costs and cost-effectiveness
of one-way SMS and two-way SMS vs. control, and between interven-
tion arms. Cost-effectiveness will be performed from both the provider
and societal perspectives.
4. Sample size calculation
With 825 women randomized in a 1:1:1 allocation ratio (275
women per arm); assuming alpha = 5%, power= 80%, 2-sided testing,
and allowing for 10% attrition;we have sufﬁcient power to detect a haz-
ard ratio (HR; treatment vs. control) of b0.65 for virologic failure assum-
ing an incidence rate of 25 per 100 person-years (PY) in the control arm,
a HR of b 0.65 for loss to follow-up, assuming an incidence rate of 25 per
100 person-years (PY) in the control arm; and a HRof b0.55 for drug re-
sistance, assuming an incidence rate of 15 per 100 PY in the control arm.
We also have sufﬁcient power to detect aHRof N2.0 for infant HIV infec-
tion or death, assuming an incidence rate of 10 per 100 PY in the control
arm. Thus, the total cohort sample is 825 women.
5. Discussion and conclusions
In theMobileWACh X trial, wewill evaluate both one-way and two-
way SMS communication as strategies to improve maternal ART
adherence and retention in HIV care and treatment programs. Invest-
ment in approaches that help women overcome barriers to ART adher-
ence can reduce MTCT, improve maternal health, reduce risk of
heterosexual transmission, and prepare women to have healthy subse-
quent pregnancies.
With the rapid expansion of mobile phone access, SMS messaging
has enormous potential to expand the reach of healthcare providers to
improve HIV-related outcomes in resource-limited settings. There is ev-
idence that two-way messaging improves clinic attendance and medi-
cation adherence, including HIV medications; [15,17], but trials
evaluating SMS potential to improve long-term maternal ART adher-
ence in PMTCT settings, or combine both MCH- and HIV-related mes-
sage content, have not been conducted. Most studies evaluating SMS
interventions for HIV-related outcomes predominantly focus onInstrument for assessment
15 items from the LifeWindows ART adherence questionnaire [38]
Medical Outcomes Study survey [39]
4-item instrument adapted from the stigma scale for chronic illnesses
(SSCI) [40]
Patient Health Questionnaire 9 (PHQ-9) [41]
Abuse Assessment Screen [42]
Household Food Insecurity Access Scale (HFIAS) [43]
stpartum
stpartum
Table 3
Primary and secondary outcomes.
Indicator Source
Primary outcomes
Maternal virologic failure HIV RNA ≥ 1000 copies/mL Maternal blood at 6 week; 6, 12, 18, 24 months postpartum
Retention Seen within 2 weeks of scheduled visits Record abstraction for scheduled clinic visits throughout study. Evaluated at 12 and 24 months
Loss to follow-up Not seen in clinical care for ≥6 months Record abstraction for scheduled clinic visits throughout study
Infant HIV infection or death HIV DNA and antibody results, and mortality Record abstraction week 6. Infant specimens 6, 12, 18, 24 months; verbal autopsy
Secondary outcomes
Drug adherence • Pharmacy: % days covered since last reﬁlla
• Self-report: % doses taken in last 30 days
Pharmacy: record abstraction throughout study
Self-report: questionnaire at study visits 6 wk., 6, 12, 18, 24 months
Maternal drug resistance OLA Resistance assay in mothers with HIV RNA exceeding 200 copies/mL
a Pharmacy data will be considered as higher quality.
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tential of this communication modality. Messaging that incorporates
education and patient support to continue ART, while simultaneously
reducing healthcare worker burden, may be an effective way to harness
the power of mHealth technology and move beyond appointment and
medication reminders.
Few mHealth intervention studies use viral load data to assess ad-
herence; [24] most have primarily relied on self-reported adherence,
which overestimates adherence [25]. We will use viral load and resis-
tance testing, in addition to self-report, to better characterize adher-
ence. We will also capture barriers to adherence reported during
study visits, and collect “real-time” qualitative data from women in
the two-way arm who relay adherence related information via SMS re-
sponses. A recent meta-analysis found that two-way SMS provided a
23% increase in adherence tomedications, while one-way SMS provided
no beneﬁt [23]; however, none of the studies included in this analysis
directly evaluated or compared two-way vs. one-way SMS within the
same study, population, or setting. One-way SMS that incorporate edu-
cation and counseling, and support maternal and child health in addi-
tion to medication adherence, could be effective in PMTCT settings. If
one-way SMS are shown to be effective they may be easier to imple-
ment or incorporate into existingprograms than two-way SMS. Alterna-
tively, two-way SMS could enhance patient engagement through an
interactive exchange with providers, but is more expensive than one-
way SMS. In Mobile WACh X, we will evaluate potential public health
beneﬁts and cost of each intervention vs. control, and assess any incre-
mental beneﬁt of two-way vs. one-way SMS. Cost-effectiveness model-
ing will provide further insights to determine the economic impact of
implementing each approach.
The content of Mobile WACh X provides personalized, tailored,
and dynamic SMS messages that are informed by behavioral theory.
These qualities have previously been reported to be desired compo-
nents of SMS, and may enhance effectiveness of mHealth interventions
[26–30]. SMS in Mobile WACh X include the participant's preferred
name or nickname and provider name, and participants receive visit re-
minders based on their individual appointment schedule. SMS content
follows a topic schedule designed to encourage ART adherence while
recognizing concerns speciﬁc to salient events in pregnancy and the
postpartum period, such as delivery, infant prophylaxis, and weaning.
Additionally, participants are placed in a messaging “track”, which de-
liver content tailored to the participant's age group (adolescent vs.
adult), and/or key clinical characteristics (newly initiating ART or
fetal/infant loss). Infant mortality remains high among infants born to
HIV-infected mothers in Africa, [31–33] and women may lack motiva-
tion to continue ART or seek health care following a pregnancy loss.Mo-
bile WACh X's infant/fetal loss track provides these women with
support to maintain their own health during this critical time period.
Together, the Mobile WACh X tracks allow for SMS customization,
which enhances personalization and may increase effectiveness com-
pared to a universal one-size-ﬁts-all approach.
Our study is subject to some limitations. While literacy is not re-
quired for women to participate, illiterate women need to feelcomfortable with another person reading SMS to them. Many women
share their phone with a partner or family member, and only women
who have daily access to a mobile phone, and feel comfortable with in-
dividuals who share their phone reading study-related SMS, are eligible
for the study. In addition, women who receive MCH and HIV care at
multiple facilities are also ineligible. While Safaricom is the most com-
monly used mobile phone carrier in Kenya (68% of all mobile phone
subscribers) [34], women who do not have a Safaricom SIM cannot be
enrolled in the Mobile WACh X system, and are also excluded from
the study. Thus, study results may not be generalizable to women
who are not comfortable sharing SMS, receive care in multiple facilities,
or use other mobile phone carriers. In addition, we will not adjust for
multiple comparisons in our analysis which may increase the Type I
error rate.
The Mobile WACh X study is unique in its personalized and tailored
approach to provide HIV-infectedwomenwith support during and after
pregnancy, and ability to determine the optimal level of participant in-
teraction by directly evaluating potential health and economic beneﬁts
of one-way vs. two-way SMS dialogue. The study was intentionally de-
signed with a long follow-up time, beyond the recommend 12 month
period HIV-infected women are advised to continue breastfeeding
[35], to assess intervention impact beyond PMTCT and long-term dura-
bility. mHealth has been identiﬁed as a priority area for research in ef-
forts to eliminate mother-to-child HIV transmission (eMTCT) [36], but
data are lacking on the effectiveness of mHealth for HIV-related mater-
nal and infant outcomes. mHealth interventions for PMTCTmay be par-
ticularly effective if they are initiated during pregnancy, motivating
women to make positive behavior changes to beneﬁt the health of
their baby and their own health [37]. Results from our study will con-
tribute important data on the utility of SMS for PMTCT and HIV and
could help inform strategic programmatic investments to improve ma-
ternal and child health outcomes.6. Trial status
Recruitment and enrollment for the RCT began on 23 November
2015. We anticipate completing enrollment by April 2017 and all fol-
low-up activities by January 2020.Acknowledgements
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